+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of canakinumab in the cryopyrin-associated periodic syndrome



Use of canakinumab in the cryopyrin-associated periodic syndrome



New England Journal of Medicine 360(23): 2416-2425



The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056795271

Download citation: RISBibTeXText

PMID: 19494217

DOI: 10.1056/nejmoa0810787


Related references

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. Yearbook of Pediatrics 2011: 241-242, 2011

Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opinion on Biological Therapy 10(11): 1631-1636, 2010

Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology 55(4): 689-696, 2016

Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy. Pediatrics 134(5): E1468-E1473, 2014

Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan. Modern Rheumatology 23(3): 425-429, 2013

Corneal response to canakinumab in cryopyrin associated periodic fever syndrome. British Journal of Ophthalmology 97(8): 1081-1082, 2013

Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Therapeutic Advances in Musculoskeletal Disease 5(6): 315-329, 2013

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Research and Therapy 15(1): R33, 2013

AB1191Within-patient analysis during anakinra and canakinumab treatment in cryopyrin associated periodic syndrome. Annals of the Rheumatic Diseases 71(Suppl 3): 706.1-706, 2013

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics 4: 131-138, 2010

An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab. Nihon Rinsho Men'eki Gakkai Kaishi 35(1): 23-29, 2012

THU0464Safety Results from the B-Confident Registry in Canakinumab-Treated Patients with Cryopyrin-Associated Periodic Syndrome (CAPS). Annals of the Rheumatic Diseases 72(Suppl 3): A321.2-A321, 2013

Live-attenuated vaccines in a cryopyrin-associated periodic syndrome patient receiving canakinumab treatment during infancy. Clinical Case Reports 5(11): 1750-1755, 2017

THU0392Beta-confident-registry: Efficacy and safety of canakinumab in cryopyrin associated periodic syndrome - 18 month follow-up. Annals of the Rheumatic Diseases 71(Suppl 3): 288.1-288, 2013

Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study. Arthritis Care and Research 69(6): 903-911, 2017